According to a new report published by Introspective Market Research, titled, Gastroenterology Market by Type, Disease Area, and End User, The Global Gastroenterology Market Size Was Valued at USD 34.6 Billion in 2023 and is Projected to Reach USD 60.5 Billion by 2032, Growing at a CAGR of 6.4%.

2. Introduction / Market Overview

The global Gastroenterology Market is experiencing substantial growth due to rising prevalence of gastrointestinal (GI) disorders and advancements in diagnostic and therapeutic technologies. Gastroenterology encompasses devices, drugs, and services used to diagnose and manage conditions such as inflammatory bowel disease (IBD), colorectal cancer, gastroesophageal reflux disease (GERD), liver disorders, and functional GI disorders. Increasing awareness of early diagnosis and improved access to minimally invasive procedures have significantly influenced market adoption.

Technological advancements, including high-definition endoscopy, capsule endoscopy, AI-based image analysis, and innovative biologic therapies, continue to transform GI care pathways. Additionally, lifestyle-related digestive conditions and aging populations across major economies have further accelerated demand for advanced gastroenterology solutions. Growing investments in research and clinical innovations are expected to drive long-term market expansion.

3. Market Segmentation

The Gastroenterology Market is segmented into Segment A, Segment B, and Segment C.

• By Segment A, the market is categorized into Diagnostics, Therapeutics, Endoscopy Devices, Imaging Systems, and Others.
• By Segment B, the market is categorized into Inflammatory Bowel Disease (IBD), GERD, Colorectal Cancer, Liver Diseases, Functional GI Disorders, and Others.
• By Segment C, the market is categorized into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others.

4. Growth Driver

A major growth driver for the Gastroenterology Market is the rising global incidence of gastrointestinal diseases such as IBD, GERD, and colorectal cancer. Sedentary lifestyles, poor dietary habits, aging populations, and increasing alcohol consumption have significantly contributed to gastrointestinal complications worldwide. Additionally, advancements in diagnostic technologies—including AI-enabled endoscopy, improved imaging modalities, and non-invasive screening tools—have enhanced early detection and clinical outcomes. Growing healthcare expenditure, coupled with broadening access to specialized GI care, is further propelling demand for innovative gastroenterology solutions and driving overall market expansion.

5. Market Opportunity

A key market opportunity lies in the rapid adoption of minimally invasive and AI-powered endoscopic procedures. With increasing patient preference for shorter recovery times and reduced complications, hospitals and clinics are upgrading their endoscopy suites with advanced imaging, robotic assistance, and real-time diagnostic software. Emerging markets in Asia-Pacific, the Middle East, and Latin America are investing heavily in modernizing GI care infrastructure, creating attractive revenue opportunities for device manufacturers and service providers. Additionally, ongoing research in biomarker-based diagnostics and next-generation biologic therapies offers significant future potential for market expansion.

6. Detailed Segmentation

Gastroenterology Market, Segmentation

The Gastroenterology Market is segmented on the basis of Segment A, Segment B, and Segment C.

Segment A: Type

The Segment A segment is further classified into Diagnostics, Therapeutics, Endoscopy Devices, Imaging Systems, and Others.
Among these, Endoscopy Devices accounted for the highest market share in 2023. Endoscopy remains the primary diagnostic tool for detecting colorectal cancer, ulcers, polyps, and functional disorders. Advancements such as high-resolution imaging, narrow-band imaging, capsule endoscopy, and robotic-assisted systems have significantly enhanced diagnostic accuracy. Increasing demand for minimally invasive procedures and routine screening programs worldwide contributes to the strong growth of this sub-segment. Continuous product innovation by global manufacturers is expected to maintain its dominant market position.

Segment B: Disease Area

The Segment B segment is further classified into Inflammatory Bowel Disease (IBD), GERD, Colorectal Cancer, Liver Diseases, Functional GI Disorders, and Others.
Among these, Inflammatory Bowel Disease (IBD) accounted for the highest market share in 2023. Rising global prevalence of Crohn’s disease and ulcerative colitis, coupled with increased awareness and access to advanced biologic therapies, has strengthened this segment. Biologic drugs, targeted therapies, and improved disease monitoring tools have significantly improved patient outcomes. The chronic nature of IBD, requiring lifelong management, continues to generate consistent demand for diagnostic and therapeutic solutions, boosting this segment’s market dominance.

7. Some of The Leading/Active Market Players Are—

• Olympus Corporation (Japan)
• Boston Scientific Corporation (U.S.)
• Medtronic plc (Ireland)
• Fujifilm Holdings Corporation (Japan)
• Ethicon Endo-Surgery (U.S.)
• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company (Japan)
• Cardinal Health (U.S.)
• Conmed Corporation (U.S.)
• Pentax Medical (Japan)
• Biogen Inc. (U.S.)
• Johnson & Johnson Services Inc. (U.S.)
• Cook Medical (U.S.)
• Novo Nordisk A/S (Denmark)
  and other active players.

8. Key Industry Developments

News 1: In February 2024, a global medical device manufacturer launched an AI-enabled endoscopy platform designed to improve early detection of colorectal cancer and polyps. The system integrates real-time image analysis, enhancing diagnostic precision and reducing oversight during endoscopic procedures.

News 2: In September 2023, a leading pharmaceutical company announced successful late-stage clinical trial results for a new biologic therapy targeting moderate-to-severe ulcerative colitis. The therapy demonstrated improved remission rates and safety outcomes, expanding treatment options for IBD patients globally.

9. Key Findings of the Study

• Endoscopy Devices dominated the Type segment in 2023.
• IBD emerged as the leading disease area.
• North America held the largest regional market share.
• Growth fueled by rising GI disease prevalence and advanced diagnostics adoption.
• AI-enabled endoscopy and biologic therapies represent major future opportunities.